BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

168 related articles for article (PubMed ID: 24608572)

  • 1. Identification of transmembrane protein 98 as a novel chemoresistance-conferring gene in hepatocellular carcinoma.
    Ng KT; Lo CM; Guo DY; Qi X; Li CX; Geng W; Liu XB; Ling CC; Ma YY; Yeung WH; Shao Y; Poon RT; Fan ST; Man K
    Mol Cancer Ther; 2014 May; 13(5):1285-97. PubMed ID: 24608572
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Clinical significance and functional role of transmembrane protein 47 (TMEM47) in chemoresistance of hepatocellular carcinoma.
    Ng KT; Yeung OW; Liu J; Li CX; Liu H; Liu XB; Qi X; Ma YY; Lam YF; Lau MY; Qiu WQ; Shiu HC; Lai MK; Lo CM; Man K
    Int J Oncol; 2020 Oct; 57(4):956-966. PubMed ID: 32945373
    [TBL] [Abstract][Full Text] [Related]  

  • 3. IFI44L is a novel tumor suppressor in human hepatocellular carcinoma affecting cancer stemness, metastasis, and drug resistance via regulating met/Src signaling pathway.
    Huang WC; Tung SL; Chen YL; Chen PM; Chu PY
    BMC Cancer; 2018 May; 18(1):609. PubMed ID: 29848298
    [TBL] [Abstract][Full Text] [Related]  

  • 4. SIRT7 regulates hepatocellular carcinoma response to therapy by altering the p53-dependent cell death pathway.
    Zhao J; Wozniak A; Adams A; Cox J; Vittal A; Voss J; Bridges B; Weinman SA; Li Z
    J Exp Clin Cancer Res; 2019 Jun; 38(1):252. PubMed ID: 31196136
    [TBL] [Abstract][Full Text] [Related]  

  • 5. MicroRNA-215 is upregulated by treatment with Adriamycin and leads to the chemoresistance of hepatocellular carcinoma cells and tissues.
    Wang L; Wang YM; Xu S; Wang WG; Chen Y; Mao JY; Tian BL
    Mol Med Rep; 2015 Oct; 12(4):5274-80. PubMed ID: 26135967
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Hepatocellular Carcinoma and Nuclear Paraspeckles: Induction in Chemoresistance and Prediction for Poor Survival.
    Kessler SM; Hosseini K; Hussein UK; Kim KM; List M; Schultheiß CS; Schulz MH; Laggai S; Jang KY; Kiemer AK
    Cell Physiol Biochem; 2019; 52(4):787-801. PubMed ID: 30946555
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Nogo-B receptor promotes the chemoresistance of human hepatocellular carcinoma via the ubiquitination of p53 protein.
    Dong C; Zhao B; Long F; Liu Y; Liu Z; Li S; Yang X; Sun D; Wang H; Liu Q; Liang R; Li Y; Gao Z; Shao S; Miao QR; Wang L
    Oncotarget; 2016 Feb; 7(8):8850-65. PubMed ID: 26840457
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Characterization of in vivo chemoresistant human hepatocellular carcinoma cells with transendothelial differentiation capacities.
    Marfels C; Hoehn M; Wagner E; Günther M
    BMC Cancer; 2013 Apr; 13():176. PubMed ID: 23547746
    [TBL] [Abstract][Full Text] [Related]  

  • 9. MEL-pep, an analog of melittin, disrupts cell membranes and reverses 5-fluorouracil resistance in human hepatocellular carcinoma cells.
    Ke M; Dong J; Wang Y; Zhang J; Zhang M; Wu Z; Lv Y; Wu R
    Int J Biochem Cell Biol; 2018 Aug; 101():39-48. PubMed ID: 29800725
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Acquired Resistance with Epigenetic Alterations Under Long-Term Antiangiogenic Therapy for Hepatocellular Carcinoma.
    Ohata Y; Shimada S; Akiyama Y; Mogushi K; Nakao K; Matsumura S; Aihara A; Mitsunori Y; Ban D; Ochiai T; Kudo A; Arii S; Tanabe M; Tanaka S
    Mol Cancer Ther; 2017 Jun; 16(6):1155-1165. PubMed ID: 28246302
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Trefoil factor 3 mediation of oncogenicity and chemoresistance in hepatocellular carcinoma is AKT-BCL-2 dependent.
    You ML; Chen YJ; Chong QY; Wu MM; Pandey V; Chen RM; Liu L; Ma L; Wu ZS; Zhu T; Lobie PE
    Oncotarget; 2017 Jun; 8(24):39323-39344. PubMed ID: 28445151
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Neuroblastoma RAS Viral Oncogene Homolog (NRAS) Is a Novel Prognostic Marker and Contributes to Sorafenib Resistance in Hepatocellular Carcinoma.
    Dietrich P; Gaza A; Wormser L; Fritz V; Hellerbrand C; Bosserhoff AK
    Neoplasia; 2019 Mar; 21(3):257-268. PubMed ID: 30685691
    [TBL] [Abstract][Full Text] [Related]  

  • 13. MiR-21 mediates sorafenib resistance of hepatocellular carcinoma cells by inhibiting autophagy via the PTEN/Akt pathway.
    He C; Dong X; Zhai B; Jiang X; Dong D; Li B; Jiang H; Xu S; Sun X
    Oncotarget; 2015 Oct; 6(30):28867-81. PubMed ID: 26311740
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Tunicamycin potentiates cisplatin anticancer efficacy through the DPAGT1/Akt/ABCG2 pathway in mouse Xenograft models of human hepatocellular carcinoma.
    Hou H; Sun H; Lu P; Ge C; Zhang L; Li H; Zhao F; Tian H; Zhang L; Chen T; Yao M; Li J
    Mol Cancer Ther; 2013 Dec; 12(12):2874-84. PubMed ID: 24130050
    [TBL] [Abstract][Full Text] [Related]  

  • 15. XLF-mediated NHEJ activity in hepatocellular carcinoma therapy resistance.
    Yang S; Wang XQ
    BMC Cancer; 2017 May; 17(1):344. PubMed ID: 28526069
    [TBL] [Abstract][Full Text] [Related]  

  • 16. BCAT1, a key prognostic predictor of hepatocellular carcinoma, promotes cell proliferation and induces chemoresistance to cisplatin.
    Zheng YH; Hu WJ; Chen BC; Grahn TH; Zhao YR; Bao HL; Zhu YF; Zhang QY
    Liver Int; 2016 Dec; 36(12):1836-1847. PubMed ID: 27246112
    [TBL] [Abstract][Full Text] [Related]  

  • 17. WM130 preferentially inhibits hepatic cancer stem-like cells by suppressing AKT/GSK3β/β-catenin signaling pathway.
    Ni CX; Qi Y; Zhang J; Liu Y; Xu WH; Xu J; Hu HG; Wu QY; Wang Y; Zhang JP
    Oncotarget; 2016 Nov; 7(48):79544-79556. PubMed ID: 27783993
    [TBL] [Abstract][Full Text] [Related]  

  • 18. ASPP2 enhances chemotherapeutic sensitivity through the down-regulation of XIAP expression in a p53 independent manner in hepatocellular carcinoma.
    Yang T; Gao Y; Liu D; Wang Y; Wu J; Liu X; Shi Y; Chen D
    Biochem Biophys Res Commun; 2019 Jan; 508(3):769-774. PubMed ID: 30528232
    [TBL] [Abstract][Full Text] [Related]  

  • 19. USP22 knockdown enhanced chemosensitivity of hepatocellular carcinoma cells to 5-Fu by up-regulation of Smad4 and suppression of Akt.
    Zhang J; Luo N; Tian Y; Li J; Yang X; Yin H; Xiao C; Sheng J; Li Y; Tang B; Li R
    Oncotarget; 2017 Apr; 8(15):24728-24740. PubMed ID: 28445968
    [TBL] [Abstract][Full Text] [Related]  

  • 20. The role of CD29-ILK-Akt signaling-mediated epithelial-mesenchymal transition of liver epithelial cells and chemoresistance and radioresistance in hepatocellular carcinoma cells.
    Jiang X; Wang J; Zhang K; Tang S; Ren C; Chen Y
    Med Oncol; 2015 May; 32(5):141. PubMed ID: 25805567
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 9.